3M
3M CO
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$24.9B
Operating marginCalculated
18.6%
Net assets to total assetsCalculated
12.5%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★★★☆position among all companies
18.6%
Growth (revenue, 4-year average)
★☆☆☆☆position among all companies
-8.3%
Capital efficiency
★★★★★position among all companies
69.1%
Revenue and profit
Performance, financial position and capital allocation
3M
Recent performance trends
3M
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$35.4 billion | US$26.2 billion | US$24.6 billion | US$24.6 billion | US$24.9 billion |
| Operating income | US$7.4 billion | US$4.4 billion | US$-10.7 billion | US$4.8 billion | US$4.6 billion |
| Net income | US$5.9 billion | US$5.8 billion | US$-7.0 billion | US$4.2 billion | US$3.2 billion |
| Total assets | US$47.1 billion | US$46.5 billion | US$50.6 billion | US$39.9 billion | US$37.7 billion |
| Shareholders' equity | US$15.0 billion | US$14.7 billion | US$4.8 billion | US$3.8 billion | US$4.7 billion |
| Net cash provided by (used in) operating activities | US$7.5 billion | US$5.6 billion | US$6.7 billion | US$1.8 billion | US$2.3 billion |
| Net cash provided by (used in) investing activities | US$-1.3 billion | US$-1.0 billion | US$-1.2 billion | US$-3.2 billion | US$1.4 billion |
| Net cash provided by (used in) financing activities | US$-6.1 billion | US$-5.3 billion | US$-3.1 billion | US$1.1 billion | US$-4.0 billion |
| Cash and cash equivalents | US$4.6 billion | US$3.7 billion | US$5.9 billion | US$5.6 billion | US$5.2 billion |
Revenue scale in the same industry
3M
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- 4 MedlineFY Dec 2025 US$28.4B
- 5 StrykerFY Dec 2025 US$25.1B
- 6 3MThis companyFY Dec 2025 US$24.9B
- 7 DanaherFY Dec 2025 US$24.6B
- 8 BECTON, Dickinson ANDFY Sep 2025 US$21.8B
- … 35 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.9 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$5.2 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-4.0 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$1.4 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$2.3 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$1.3 billion | Consolidated | Disclosed |
| Dividends paid | US$1.6 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$4.7 billion | Consolidated | Disclosed |
| Non-controlling interests | US$45.00 million | Consolidated | Disclosed |
| Net assets | US$4.7 billion | Consolidated | Disclosed |
| Net sales | US$24.9 billion | Consolidated | Disclosed |
| Operating income | US$4.6 billion | Consolidated | Disclosed |
| Net income | US$3.2 billion | Consolidated | Disclosed |
| Total assets | US$37.7 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$3.3 billion | Consolidated | Disclosed |
| Operating margin | 18.6% | Consolidated | Calculated |
| Net assets to total assets | 12.5% | Consolidated | Calculated |
| Net margin | 13.0% | Consolidated | Calculated |
| Return on equity | 69.1% | Consolidated | Calculated |